ACTU Latest Press Releases

-- December 18, 2025 --

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 Globe Newswire 8:45 AM

-- December 15, 2025 --

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma Globe Newswire 8:45 AM

-- October 30, 2025 --

Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP) AB Digital Inc 2:49 PM

-- September 22, 2025 --

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months Globe Newswire 8:45 AM

-- September 11, 2025 --

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option Globe Newswire 4:01 PM

-- September 10, 2025 --

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock Globe Newswire 8:31 AM

-- September 9, 2025 --

Actuate Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:07 PM

-- August 6, 2025 --

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer Globe Newswire 8:45 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software